


# Study of Brentuximab vedotin on relapsed/refractory systemic anaplastic large cell lymphoma confirms the activity in elderly patients, the duration of the clinical response independently by the transplant consolidation and the relevance of the CR status after 4 cycles in term of final response



## Primary endpoints

- best response
  - observed after a median of 4 cycles in 77.5%
  - 47.5% patients with complete response
  - **64.2%** in the elderly subset

## Secondary endpoints

- overall response rate (end of the treatment)
  - 62.5%
- duration of response
  - 15/18 patients are still in complete response
- survival
  - progression free survival 39.1% at 24 months
  - disease free survival 54% at 24 months
- safety profile
  - treatment was well tolerated
  - no death has been linked to drug toxicity